Phio Pharmaceuticals Secures Agreement with US Manufacturer for Drug Substance Development

Phio Pharmaceuticals has entered a comprehensive drug substance development services agreement with a US manufacturer to provide analytical and process development and cGMP manufacture of its lead clinical development compound PH-762. This is a critical next step in advancing Phio's intratumoral program to treat cutaneous carcinomas. The company is currently enrolling patients for the 5th and final cohort in its Phase 1b dose escalation study for cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma.

Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, has entered into a comprehensive drug substance development services agreement with a U.S.-based manufacturer for its lead compound PH-762. The agreement, which covers analytical and process development services along with cGMP manufacturing, marks a significant milestone in advancing Phio's intratumoral program for treating cutaneous carcinomas.

The contract development and manufacturing agreement (CDMO) will provide Phio with the necessary analytical and process development expertise, as well as cGMP manufacturing capabilities for PH-762. This is a critical step in Phio's ongoing Phase 1b dose escalation study, which is currently enrolling patients for the 5th and final cohort. The study is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma.

"We are delighted to be partnering with an organization known for its quality and expertise in oligonucleotide chemistry sequencing," said Mr. Bitterman, Phio's President and CEO. "Additionally, we value the strategic advantages to our management team of working with a U.S. based organization."

About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer.

Phio is currently enrolling patients for the 5th and expected final cohort in its Phase 1b dose escalation study for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

For additional information, visit the Company's website, [www.phiopharma.com](http://www.phiopharma.com).

References:
[1] https://www.stocktitan.net/news/PHIO/phio-pharmaceuticals-announces-agreement-with-u-s-manufacturing-u580ibvr7ygf.html